Combination treatments combine two or more individual treatments. We know from experience in complex diseases, such as cancer, HIV, rheumatoid arthritis and Hepatitis C, that combination treatments have the potential to deliver significant clinical benefits to patients.

As treatments included within a combination are often developed by different manufacturers, they tend to be priced independently of each other. Intercompany discussions on price are not permitted, as companies are not legally allowed to work together to make pricing decisions due to strict competition law in the UK.

Takeda is guided by an unwavering commitment to put the patient first in everything that we do. Takeda recognises the importance of collaboration. We encourage feedback, critique, and debate of the two Whitepapers so that we can contribute an implementable solution that represents perspectives from all stakeholders.

In partnership with experts from academia, clinical and patient communities, and with expert input from NICE and the NHS, we have developed a proposed solution that has the potential to improve patient access to combination treatments.

Takeda recognises the importance of collaboration. We encourage feedback, critique, and debate of the two Whitepapers so that we can contribute an implementable solution that represents perspectives from all stakeholders.

To find out more, visit www.takeda.com/en-gb/what-we-do/combination-treatments or contact the team on combinationmedicinesUK@takeda.com.

The solution is explained within two Whitepapers which aim to contribute to the options being explored by other stakeholders to find transactable and implementable solutions that align with current NICE appraisal and NHS England commercial methods.

The Voluntary Arbitration Framework proposes a standard operating procedure to support compliant dialogue and agreement between pharmaceutical companies on the value attributed to each treatment within a combination.

The Value Attribution Framework proposes an economic methodology that defines a fair division of value across the treatments in a combination.

C-ANPROM/GB/OG/0001
Date of preparation: July 2021

1 EFPIA and IQVIA., EFPIA Patients W.A.I.T. Indicator 2019 Survey. EFPIA. 2020. Pg 49

IN 2019, ONLY 56% of licensed combination treatments are routinely available to patients on the NHS, in the UK.